Isoprostane in systemic sclerosis: A systematic review and meta-analysis
Authors:
- 4 May 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 29 (3) , 470-475
Abstract
Objectives: To further the knowledge of oxidative stress in systemic sclerosis (SSc), we performed a systematic review and meta-analysis on studies measuring isoprostane, a vasoactive agent deriving from arachidonic acid and implicated in the vasculopathy of SSc. Methods: Systematic search following the PRISMA guidelines in PubMed and EMBASE between January-1990/December-2017 using the terms: oxidative stress, isoprostane, systemic sclerosis and scleroderma. Results: After the screening process, 8 studies including 240 SSc patients and 192 controls were included in the systematic review and meta-analysis, 6 investigating urinary and 2 serum isoprostane: random effect meta-analysis revealed isoprostane overgeneration in SSc (p < .001) with wide heterogeneity (I2 = 75%). Subgroup analysis on urinary isoprostane favoured excess excretion in SSc (p = .009) with slightly lower heterogeneity (I2 = 67%); further subgroup analysis according to unit of measurement revealed no increased isoprostane excretion when expressed as pg/mg creatinine but increased when expressed as pmol/mmol creatinine (p = .05) with medium heterogeneity (I2 = 32%). Subgroup analysis on serum isoprostane favoured overproduction in SSc (p < .0001) with no heterogeneity. Conclusion: There is some evidence for isoprostane overgeneration in SSc that confirms the occurrence of oxidative stress in this setting: further prospective studies with specified outcomes are needed to evaluate the prognostic value of this functional biomarker.Keywords
This publication has 35 references indexed in Scilit:
- Interpretation of random effects meta-analysesBMJ, 2011
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals of the Rheumatic Diseases, 2010
- A significant proportion of F2-isoprostanes in human urine are excreted as glucuronide conjugatesAnalytical Biochemistry, 2010
- Key issues in F2-isoprostane analysisBiochemical Society Transactions, 2008
- The case of the misleading funnel plotBMJ, 2006
- Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosisFree Radical Biology and Medicine, 2006
- Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical featuresRheumatology, 2005
- Urinary 8-epi-PGF2α and its endogenous β-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stressBiochemical and Biophysical Research Communications, 2005
- Increased urinary F2‐isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: Effect of cold exposureArthritis & Rheumatism, 2002
- Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth musclesBritish Journal of Pharmacology, 2001